关于我们

ENKAM Pharmaceuticals A/S Commercial Partnership with STEMCELL Technologies Inc ENKAM Pharmaceuticals A/S (ENKAM), a privately held Danish biopharmaceutical development company focused on cancer and central nervous system disorders, is pleased to announce that it has signed a licensing and development agreement with STEMCELL Technologies Inc.
STEMCELL Technologies Inc. Obtains License from iPS Academia Japan for Induced Pluripotent Stem Cell Technologies STEMCELL Technologies has signed a patent license agreement with iPS Academia Japan, Inc. to license and commercialize iPS Academia Japan, Inc.'s patented technologies for induced pluripotent stem cell (iPS cell) research
STEMCELL Technologies Receives Government of Canada Support to Develop New Cell Isolation Technology that will Enable Advancements in the Study of the Immune Response to HIV and the Development of HIV Vaccines STEMCELL Technologies announced that the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) will provide up to $1.5 million in financial support for the development of cell isolation technology that will further basic and translational HIV research as well as broader research in infectious disease
The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids
STEMCELL Technologies wins Support from Western Innovation (WINN) Initiative for Commercialization of 3D Cell Culture Platform STEMCELL Technologies has received $949,500 in repayable assistance from the Western Innovation (WINN) Initiative for an exciting project to develop tools and assays for three-dimensional (3D) cell culture
STEMCELL Technologies Named Company of the Year by BIOTECanada STEMCELL Technologies Inc. will be presented with the Biotech Company of the Year award by BIOTECanada at the BIO International Convention in Philadelphia
Lawson and STEMCELL Technologies Announce Partnership for Commercialization of Tools for Parkinson's Disease Research Lawson Health Research Institute (Lawson) and STEMCELL Technologies Inc. announced that they have signed a license agreement giving STEMCELL global exclusive rights to commercialize novel tools for Parkinson's Disease research